Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2014 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Total Non-Current Liabilities of $22.2 million for Q1 2026, little changed year-over-year from $22.1 million in Q1 2025, and down 1.09% quarter-over-quarter from $22.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Total Non-Current Liabilities for 10 consecutive years, with $22.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed 0.38% year-over-year to $22.2 million; the TTM figure through Mar 2026 stood at $22.2 million (changed 0.38% YoY), while the FY2025 annual figure was $22.4 million, up 5.0% from the prior year.
- Total Non-Current Liabilities retreated to $22.2 million in Q1 2026 per GYRE's latest filing, from $22.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $38.0 million in Q4 2023 and bottomed at $1.8 million in Q3 2023.
- Historically, Total Non-Current Liabilities has averaged $18.6 million across 5 years, with a median of $20.7 million in 2024.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 1699.95% in 2024 and fell as far as 43.88% in 2024.
- Gyre Therapeutics' Total Non-Current Liabilities stood at $12.5 million in 2022, then jumped by 203.25% to $38.0 million in 2023, then tumbled by 43.88% to $21.3 million in 2024, then advanced by 5.0% to $22.4 million in 2025, then decreased by 1.09% to $22.2 million in 2026.
- Business Quant data shows GYRE's Total Non-Current Liabilities at $22.2 million in Q1 2026, $22.4 million in Q4 2025, and $18.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 31.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.60 Mn |
| Mar 31, 2026 | 22.16 Mn |
| Dec 31, 2025 | 22.40 Mn |
| Sep 30, 2025 | 18.75 Mn |
| Jun 30, 2025 | 20.00 Mn |
| Mar 31, 2025 | 22.08 Mn |
| Dec 31, 2024 | 21.34 Mn |
| Sep 30, 2024 | 16.00 Mn |
| Jun 30, 2024 | 27.54 Mn |
| Mar 31, 2024 | 33.19 Mn |
| Dec 31, 2023 | 38.02 Mn |
| Sep 30, 2023 | 1.78 Mn |
| Jun 30, 2023 | 2.79 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 12.54 Mn |
| Dec 31, 2018 | 4.98 Mn |
| Sep 30, 2018 | 3.47 Mn |
| Jun 30, 2018 | 2.58 Mn |
| Mar 31, 2018 | 3.04 Mn |
| Dec 31, 2017 | 8.74 Mn |